Abstract
Accumulation of amyloid β (Aβ) and its aggregates in the ageing central nervous system is regarded synonymous to Alzheimer’s disease (AD) pathology. Despite unquestionable advances in mechanistic and diagnostic aspects of the disease understanding, the primary cause of Aβ accumulation as well as its in vivo roles remains elusive; nonetheless, the majority of the efforts to address pathological mechanisms for therapeutic development are focused towards moderating Aβ accumulation in the brain. More recently, Aβ deposition has been identified in the eye and is linked with distinct age-related diseases including age-related macular degeneration, glaucoma as well as AD. Awareness of the Aβ accumulation in these markedly different degenerative disorders has led to an increasing body of work exploring overlapping mechanisms, a prospective biomarker role for Aβ and the potential to use retina as a model for brain related neurodegenerative disorders. Here, we present an integrated view of current understanding of the retinal Aβ deposition discussing the accumulation mechanisms, anticipated impacts and outlining ameliorative approaches that can be extrapolated to the retina for potential therapeutic benefits. Further longitudinal investigations in humans and animal models will determine retinal Aβ association as a potential pathognomonic, diagnostic or prognostic biomarker.
Similar content being viewed by others
Abbreviations
- AD:
-
Alzheimer’s disease
- AMD:
-
Age-related macular degeneration
- Aβ:
-
Amyloid beta
- RGC:
-
Retinal ganglion cell
- APP:
-
Amyloid precursor protein
- RNFL:
-
Retinal nerve fibre layer
- PERG:
-
Pattern electroretinogram
- VEP:
-
Visual evoked potential
- OCT:
-
Optical coherence tomography
- RPE:
-
Retinal pigment epithelium
- BrM:
-
Bruch’s membrane
- IOP:
-
Intra ocular pressure
- BDNF:
-
Brain derived neurotrophic factor
- CNTF:
-
Ciliary neurotrophic factor
- GDNF:
-
Glial derived neurotrophic factor
- Arc:
-
Activity regulated cytoskeleton-associated protein
- BACE:
-
β Secretase
- ACE:
-
Angiotensin converting enzyme
- AGE:
-
Advanced glycation end product
- VEGF:
-
Vascular endothelial growth factor
- INL:
-
Inner nuclear layer
- ROS:
-
Reactive oxygen species
- ONH:
-
Optic nerve head
- NSAID:
-
Non-steroidal anti-inflammatory drugs
- HRT:
-
Hormone replacement therapy
- LH:
-
Luteinizing hormone
- GRH:
-
Gonadotrophin releasing hormone
- SOD:
-
Superoxide dismutase
References
Gupta VK et al (2016) Amyloid beta accumulation and Inner retinal degenerative changes in Alzheimer’s disease transgenic mouse. Neurosci Lett 623:52–56
Gupta VB et al (2005) Aluminium in Alzheimer’s disease: are we still at a crossroad? Cell Mol Life Sci 62:143–158
Iseri PK, Altinas O, Tokay T, Yuksel N (2006) Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 26:18–24
Casson RJ, Chidlow G, Wood JP, Crowston JG, Goldberg I (2012) Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol 40:341–349
Gupta V, You Y, Li J, Gupta V, Golzan M, Klistorner A, van den Buuse M, Graham S (2014) BDNF impairment is associated with age-related changes in the inner retina and exacerbates experimental glaucoma. Biochim Biophys Acta 1842:1567–1578
Sivak JM (2013) The aging eye: common degenerative mechanisms between the Alzheimer’s brain and retinal disease. Invest Ophthalmol Vis Sci 54:871–880
Ning A, Cui J, To E, Ashe KH, Matsubara J (2008) Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci 49:5136–5143
Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K, Hampel H (2014) CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement 10:381–392
Zhao Y, Bhattacharjee S, Jones BM, Hill JM, Clement C, Sambamurti K, Dua P, Lukiw WJ (2015) Beta-amyloid precursor protein (betaAPP) processing in Alzheimer’s disease (AD) and age-related macular degeneration (AMD). Mol Neurobiol 52:533–544
Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG (2009) Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease. Graefes Arch Clin Exp Ophthalmol 247:1213–1221
Ding JD et al (2011) Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci USA 108:E279–E287
Almasieh M, Wilson AM, Morquette B, Vargas JLC, Di Polo A (2012) The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res 31:152–181
Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121:2081–2090
Woo SJ, Park KH, Ahn J, Choe JY, Jeong H, Han JW, Kim TH, Kim KW (2012) Cognitive impairment in age-related macular degeneration and geographic atrophy. Ophthalmology 119:2094–2101
Tamura H et al (2006) High frequency of open-angle glaucoma in Japanese patients with Alzheimer’s disease. J Neurol Sci 246:79–83
Keenan TD, Goldacre R, Goldacre MJ (2014) Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions. JAMA Ophthalmol 132:63–68
Kessing LV, Lopez AG, Andersen PK, Kessing SV (2007) No increased risk of developing Alzheimer disease in patients with glaucoma. J Glaucoma 16:47–51
Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2:a006346
Wu N, Rao X, Gao Y, Wang J, Xu F (2013) Amyloid-beta deposition and olfactory dysfunction in an Alzheimer’s disease model. J Alzheimers Dis 37:699–712
Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL (2011) Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 54(Suppl 1):S204–S217
Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S (2009) Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer’s disease. Invest Ophthalmol Vis Sci 50:793–800
Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, Tan Z (2009) Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer’s transgenic mice. Am J Pathol 175:2099–2110
Bentley P, Driver J, Dolan RJ (2008) Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer’s disease and health. Brain 131:409–424
Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL (2007) Retinal abnormalities in early Alzheimer’s disease. Invest Ophthalmol Vis Sci 48:2285–2289
Jackson GR, Owsley C (2003) Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 21:709–728
Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J (2007) Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett 420:97–99
Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F (2001) Morphological and functional retinal impairment in Alzheimer’s disease patients. Clin Neurophysiol 112:1860–1867
McKee AC, Au R, Cabral HJ, Kowall NW, Seshadri S, Kubilus CA, Drake J, Wolf PA (2006) Visual association pathology in preclinical Alzheimer disease. J Neuropathol Exp Neurol 65:621–630
Moncaster JA et al (2010) Alzheimer’s disease amyloid-β links lens and brain pathology in Down syndrome. PLoS One 5:e10659
Fotiou DF, Brozou CG, Haidich AB, Tsiptsios D, Nakou M, Kabitsi A, Giantselidis C, Fotiou F (2007) Pupil reaction to light in Alzheimer’s disease: evaluation of pupil size changes and mobility. Aging Clin Exp Res 19:364–371
Isas JM, Luibl V, Johnson LV, Kayed R, Wetzel R, Glabe CG, Langen R, Chen J (2010) Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci 51:1304–1310
Liu C, Cao L, Yang S, Xu L, Liu P, Wang F, Xu D (2015) Subretinal injection of amyloid-beta peptide accelerates RPE cell senescence and retinal degeneration. Int J Mol Med 35:169–176
Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118
Malek G et al (2005) Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci U S A 102:11900–11905
Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 70:440–444
Verghese PB et al (2013) ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci 110:E1807–E1816
Klaver CC, Ott A, Hofman A, Assink JJ, Breteler MM, de Jong PT (1999) Is age-related maculopathy associated with Alzheimer’s Disease? The Rotterdam Study. Am J Epidemiol 150:963–968
Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M (2011) Age-related macular degeneration (AMD): Alzheimer’s disease in the eye? J Alzheimers Dis 24:615–631
Guo L et al (2007) Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 104:13444–13449
Kipfer-Kauer A, McKinnon SJ, Frueh BE, Goldblum D (2010) Distribution of amyloid precursor protein and amyloid-beta in ocular hypertensive C57BL/6 mouse eyes. Curr Eye Res 35:828–834
Goldblum D, Kipfer-Kauer A, Sarra G-M, Wolf S, Frueh BE (2007) Distribution of amyloid precursor protein and amyloid-β immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest Ophthalmol Vis Sci 48:5085–5090
Janciauskiene S, Krakau T (2001) Alzheimer’s peptide: a possible link between glaucoma, exfoliation syndrome and Alzheimer’s disease. Acta Ophthalmol Scand 79:328–329
Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H (2005) Vitreous fluid levels of β-amyloid(1–42) and tau in patients with retinal diseases. Jpn J Ophthalmol 49:106–108
Bayer AU, Ferrari F (2002) Severe progression of glaucomatous optic neuropathy in patients with Alzheimer’s disease. Eye (Lond) 16:209–212
Trillaud-Doppia E, Paradis-Isler N, Boehm J (2016) A single amino acid difference between the intracellular domains of amyloid precursor protein and amyloid-like precursor protein 2 enables induction of synaptic depression and block of long-term potentiation. Neurobiol Dis 91:94–104
Belaidi AA, Bush AI (2015) Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics. J Neurochem. doi:10.1111/jnc.13425
Avan A, Hoogenraad TU (2015) Zinc and copper in Alzheimer’s disease. J Alzheimers Dis 46:89–92
Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA 99:7705–7710
Lengyel I et al (2007) High concentration of zinc in sub-retinal pigment epithelial deposits. Exp Eye Res 84:772–780
Age-Related Eye Disease Study 2 Research Group (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309:2005–2015
Greenough MA, Camakaris J, Bush AI (2013) Metal dyshomeostasis and oxidative stress in Alzheimer’s disease. Neurochem Int 62:540–555
Hahn P, Qian Y, Dentchev T, Chen L, Beard J, Harris ZL, Dunaief JL (2004) Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci USA 101:13850–13855
Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G (2010) Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta 1802:2–10
Zhang K et al (2011) Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA 108:6241–6245
Garzon DJ, Fahnestock M (2007) Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 27:2628–2635
Peng S et al (2009) Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer’s disease. J Neurosci 29:9321–9329
Garzon D, Yu G, Fahnestock M (2002) A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer’s disease parietal cortex. J Neurochem 82:1058–1064
Lim YY et al (2015) APOE and BDNF polymorphisms moderate amyloid beta-related cognitive decline in preclinical Alzheimer’s disease. Mol Psychiatry 20:1322–1328
Echeverria V, Berman DE, Arancio O (2007) Oligomers of beta-amyloid peptide inhibit BDNF-induced arc expression in cultured cortical Neurons. Curr Alzheimer Res 4:518–521
Wong J, Higgins M, Halliday G, Garner B (2012) Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer’s disease. Neuroscience 210:363–374
Cattaneo A, Capsoni S, Paoletti F (2008) Towards non invasive nerve growth factor therapies for Alzheimer’s disease. J Alzheimers Dis 15:255–283
Lambiase A, Coassin M, Tirassa P, Mantelli F, Aloe L (2009) Nerve growth factor eye drops improve visual acuity and electrofunctional activity in age-related macular degeneration: a case report. Ann Ist Super Sanita 45:439–442
Pease ME et al (2009) Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci 50:2194–2200
Garcia P et al (2010) Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer’s disease. J Neurosci 30:7516–7527
Lebrun-Julien F, Morquette B, Douillette A, Saragovi HU, Di Polo A (2009) Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Mol Cell Neurosci 40:410–420
Gupta VK, You Y, Klistorner A, Graham SL (2012) Shp-2 regulates the TrkB receptor activity in the retinal ganglion cells under glaucomatous stress. Biochim Biophys Acta 1822:1643–1649
Jeronimo-Santos A et al (2015) Dysregulation of TrkB receptors and BDNF function by amyloid-beta peptide is mediated by calpain. Cereb Cortex 25:3107–3121
Fombonne J, Rabizadeh S, Banwait S, Mehlen P, Bredesen DE (2009) Selective vulnerability in Alzheimer’s disease: amyloid precursor protein and p75(NTR) interaction. Ann Neurol 65:294–303
Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T (2009) Inflammation in Alzheimer’s disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 87:181–194
Rogers RS, Dharsee M, Ackloo S, Sivak JM, Flanagan JG (2012) Proteomics analyses of human optic nerve head astrocytes following biomechanical strain. Mol Cell Proteomics 11(M111):012302
Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV (2004) Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 78:243–256
Buschini E, Piras A, Nuzzi R, Vercelli A (2011) Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol 95:14–25
Zhao T et al (2015) Age-related increases in amyloid beta and membrane attack complex: evidence of inflammasome activation in the rodent eye. J Neuroinflamm 12:121
Alexandrov PN, Pogue A, Bhattacharjee S, Lukiw WJ (2011) Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer’s disease. Neuroreport 22:623–627
Fonseca MI, Chu SH, Berci AM, Benoit ME, Peters DG, Kimura Y, Tenner AJ (2011) Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer’s disease. J Neuroinflamm 8:4
Stasi K, Nagel D, Yang X, Wang RF, Ren L, Podos SM, Mittag T, Danias J (2006) Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes. Invest Ophthalmol Vis Sci 47:1024–1029
Tezel G (2008) TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res 173:409–421
Zeng C, Lee JT, Chen H, Chen S, Hsu CY, Xu J (2005) Amyloid-beta peptide enhances tumor necrosis factor-alpha-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes. J Neurochem 94:703–712
Wang WH, McNatt LG, Pang IH, Hellberg PE, Fingert JH, McCartney MD, Clark AF (2008) Increased expression of serum amyloid A in glaucoma and its effect on intraocular pressure. Invest Ophthalmol Vis Sci 49:1916–1923
Bosco A et al (2008) Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2 J mouse model of glaucoma. Invest Ophthalmol Vis Sci 49:1437–1446
Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE (2009) Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci 29:4252–4262
Zhang H, Ma Q, Zhang YW, Xu H (2012) Proteolytic processing of Alzheimer’s beta-amyloid precursor protein. J Neurochem 120(Suppl 1):9–21
Yamamoto R, Yoneda S, Hara H (2004) Neuroprotective effects of beta-secretase inhibitors against rat retinal ganglion cell death. Neurosci Lett 370:61–64
Cai J et al (2012) beta-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med 4:980–991
Devi L, Ohno M (2013) Mechanisms that lessen benefits of beta-secretase reduction in a mouse model of Alzheimer’s disease. Transl Psychiatry 3:e284
Boulton ME, Cai J, Grant MB (2008) gamma-Secretase: a multifaceted regulator of angiogenesis. J Cell Mol Med 12:781–795
Gupta VB, Gupta VK, Martins R (2013) Semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369:1660–1661
Ohno-Matsui K (2011) Parallel findings in age-related macular degeneration and Alzheimer’s disease. Prog Retin Eye Res 30:217–238
Foureaux G et al (2013) Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. Invest Ophthalmol Vis Sci 54:4296–4306
Barker R, Love S, Kehoe PG (2010) Plasminogen and plasmin in Alzheimer’s disease. Brain Res 1355:7–15
Chintala SK (2016) Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma. Exp Eye Res 143:17–27
Gupta V, Wall RV, Gupta V, Graham S (2016) Interaction with neuroserpin may be involved in the impairment of protease mediated amyloid β clearance from the brain and retina. Alzheimers Dement 11:864–865
De Kimpe L, van Haastert ES, Kaminari A, Zwart R, Rutjes H, Hoozemans JJ, Scheper W (2013) Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Abeta pathology at the lysosome. Age (Dordr) 35:673–687
Zheng L, Cedazo-Minguez A, Hallbeck M, Jerhammar F, Marcusson J, Terman A (2012) Intracellular distribution of amyloid beta peptide and its relationship to the lysosomal system. Transl Neurodegener 1:19
Van Broeck B et al (2008) Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer’s disease. Neurobiol Aging 29:241–252
Wang C, Sun B, Zhou Y, Grubb A, Gan L (2012) Cathepsin B degrades amyloid-beta in mice expressing wild-type human amyloid precursor protein. J Biol Chem 287:39834–39841
Im E, Kazlauskas A (2007) The role of cathepsins in ocular physiology and pathology. Exp Eye Res 84:383–388
Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, Bu G (2012) Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem 287:44593–44601
Viiri J et al (2013) Autophagy activation clears ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human retinal pigment epithelial cells. PLoS One 8:e69563
Kitaoka Y, Munemasa Y, Kojima K, Hirano A, Ueno S, Takagi H (2013) Axonal protection by Nmnat3 overexpression with involvement of autophagy in optic nerve degeneration. Cell Death Dis 4:e860
Rodriguez-Muela N, Germain F, Marino G, Fitze PS, Boya P (2012) Autophagy promotes survival of retinal ganglion cells after optic nerve axotomy in mice. Cell Death Differ 19:162–169
Hansson Petersen CA et al (2008) The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 105:13145–13150
Ren R, Zhang Y, Li B, Wu Y, Li B (2011) Effect of beta-amyloid (25-35) on mitochondrial function and expression of mitochondrial permeability transition pore proteins in rat hippocampal neurons. J Cell Biochem 112:1450–1457
Schrier SA, Falk MJ (2011) Mitochondrial disorders and the eye. Curr Opin Ophthalmol 22:325–331
Hung CH, Ho YS, Chang RC (2010) Modulation of mitochondrial calcium as a pharmacological target for Alzheimer’s disease. Ageing Res Rev 9:447–456
Chindasub P, Lindsey JD, Duong-Polk K, Leung CK, Weinreb RN (2013) Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells. Invest Ophthalmol Vis Sci 54:96–102
Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, Smith MA (2010) Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 59:290–294
Tamagno E, Guglielmotto M, Monteleone D, Tabaton M (2012) Amyloid-beta production: major link between oxidative stress and BACE1. Neurotox Res 22:208–219
Chiras D, Kitsos G, Petersen MB, Skalidakis I, Kroupis C (2015) Oxidative stress in dry age-related macular degeneration and exfoliation syndrome. Crit Rev Clin Lab Sci 52:12–27
Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN (2009) Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 14:469–486
Wang MY, Ross-Cisneros FN, Aggarwal D, Liang CY, Sadun AA (2009) Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer’s disease. Acta Neuropathol 118:381–389
Nicolakakis N, Hamel E (2011) Neurovascular function in Alzheimer’s disease patients and experimental models. J Cereb Blood Flow Metab 31:1354–1370
Hoh Kam J, Lenassi E, Jeffery G (2010) Viewing ageing eyes: diverse sites of amyloid beta accumulation in the ageing mouse retina and the up-regulation of macrophages. PLoS One 5:e13127
Wong TY et al (2002) Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study. Stroke 33:1487–1492
Gentile MT et al (2004) Mechanisms of soluble beta-amyloid impairment of endothelial function. J Biol Chem 279:48135–48142
Provias J, Jeynes B (2014) The role of the blood–brain barrier in the pathogenesis of senile plaques in Alzheimer’s disease. Int J Alzheimers Dis 2014:191863
Austin SA, Santhanam AV, Hinton DJ, Choi DS, Katusic ZS (2013) Endothelial nitric oxide deficiency promotes Alzheimer’s disease pathology. J Neurochem 127:691–700
Eldred WD, Blute TA (2005) Imaging of nitric oxide in the retina. Vision Res 45:3469–3486
Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN (2007) Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144:950–960
Graham SL, Butlin M, Lee M, Avolio AP (2013) Central blood pressure, arterial waveform analysis, and vascular risk factors in glaucoma. J Glaucoma 22:98–103
Galimberti D, Scarpini E (2016) Emerging amyloid disease-modifying drugs for Alzheimer’s disease. Expert Opin Emerg Drugs 21:5–7
Schneider LS et al (2014) Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 275:251–283
Rakover I, Arbel M, Solomon B (2007) Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis 4:392–402
Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5:481–489
Ghai K, Zelinka C, Fischer AJ (2010) Notch signaling influences neuroprotective and proliferative properties of mature Muller glia. J Neurosci 30:3101–3112
Kukar TL et al (2008) Substrate-targeting gamma-secretase modulators. Nature 453:925–929
Solomon A, Kivipelto M (2009) Cholesterol-modifying strategies for Alzheimer’s disease. Expert Rev Neurother 9:695–709
Pike CJ, Carroll JC, Rosario ER, Barron AM (2009) Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol 30:239–258
Henderson VW (2014) Alzheimer’s disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol 142:99–106
Butchart J, Birch B, Bassily R, Wolfe L, Holmes C (2013) Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Dis Assoc Disord 27:153–156
Blair JA, Palm R, Chang J, McGee H, Zhu X, Wang X, Casadesus G (2016) Luteinizing hormone downregulation but not estrogen replacement improves ovariectomy-associated cognition and spine density loss independently of treatment onset timing. Horm Behav 78:60–66
Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MB (2008) Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis 15:211–222
Craggs L, Kalaria RN (2011) Revisiting dietary antioxidants, neurodegeneration and dementia. Neuroreport 22:1–3
Rhone M, Basu A (2008) Phytochemicals and age-related eye diseases. Nutr Rev 66:465–472
Chew EY, Clemons TE, Agron E, Sperduto RD, Sangiovanni JP, Kurinij N, Davis MD, Age-Related Eye Disease Study Research Group (2013) Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no 35. Ophthalmology 120:1604–1611 e4
Caprioli J, Munemasa Y, Kwong JM, Piri N (2009) Overexpression of thioredoxins 1 and 2 increases retinal ganglion cell survival after pharmacologically induced oxidative stress, optic nerve transection, and in experimental glaucoma. Trans Am Ophthalmol Soc 107:161–165
Giuffrida ML, Caraci F, De Bona P, Pappalardo G, Nicoletti F, Rizzarelli E, Copani A (2010) The monomer state of beta-amyloid: where the Alzheimer’s disease protein meets physiology. Rev Neurosci 21:83–93
Wang LL, Sun Y, Huang K, Zheng L (2013) Curcumin, a potential therapeutic candidate for retinal diseases. Mol Nutr Food Res 57:1557–1568
Takeda A, Takada S, Ando M, Itagaki K, Tamano H, Suzuki M, Iwaki H, Oku N (2010) Impairment of recognition memory and hippocampal long-term potentiation after acute exposure to clioquinol. Neuroscience 171:443–450
Lannfelt L et al (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7:779–786
Amijee H, Scopes DI (2009) The quest for small molecules as amyloid inhibiting therapies for Alzheimer’s disease. J Alzheimers Dis 17:33–47
Wilcock DM et al (2006) Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26:5340–5346
Wang A, Das P, Switzer RC 3rd, Golde TE, Jankowsky JL (2011) Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci 31:4124–4136
Lannfelt L, Moller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P (2014) Perspectives on future Alzheimer therapies: amyloid-beta protofibrils—a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimers Res Ther 6:16
Vellas B et al (2013) Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 9:438–444
Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6:108–119
Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol 14:11–20
Davtyan H et al (2013) Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: prelude to a clinical trial. J Neurosci 33:4923–4934
Wisniewski T, Goni F (2015) Immunotherapeutic approaches for Alzheimer’s disease. Neuron 85:1162–1176
Lambracht-Washington D, Rosenberg RN (2015) A noninflammatory immune response in aged DNA Abeta42-immunized mice supports its safety for possible use as immunotherapy in AD patients. Neurobiol Aging 36:1274–1281
Demattos RB et al (2012) A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer’s disease mice. Neuron 76:908–920
Salloway S et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370:322–333
Doody RS et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311–321
Cramer PE et al (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335:1503–1506
LaClair KD, Manaye KF, Lee DL, Allard JS, Savonenko AV, Troncoso JC, Wong PC (2013) Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener 8:18
Ulrich JD et al (2013) In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener 8:13
Walker D, Lue LF, Paul G, Patel A, Sabbagh MN (2015) Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease. Expert Opin Investig Drugs 24:393–399
Wu HM et al (2009) Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 34:2344–2357
Kim TW, Kim DM, Park KH, Kim H (2002) Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia. Korean J Ophthalmol 16:1–7
Osborne NN (2009) Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 87:450–454
Porter T, Bharadwaj P, Groth D, Paxman A, Laws SM, Martins RN, Verdile G (2016) The effects of latrepirdine on amyloid-beta aggregation and toxicity. J Alzheimers Dis 50:895–905
Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 25:CD005593
Almasieh M, MacIntyre JN, Pouliot M, Casanova C, Vaucher E, Kelly ME, Di Polo A (2013) Acetylcholinesterase inhibition promotes retinal vasoprotection and increases ocular blood flow in experimental glaucoma. Invest Ophthalmol Vis Sci 54:3171–3183
Ong WY, Farooqui T, Kokotos G, Farooqui AA (2015) Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. ACS Chem Neurosci 6:814–831
Landa G, Butovsky O, Shoshani J, Schwartz M, Pollack A (2008) Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res 33:1011–1013
Nagahara AH et al (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 15:331–337
Park JH, Strittmatter SM (2007) Nogo receptor interacts with brain APP and Abeta to reduce pathologic changes in Alzheimer’s transgenic mice. Curr Alzheimer Res 4:568–570
Liu X, Zuo Z, Liu W, Wang Z, Hou Y, Fu Y, Han Y (2014) Upregulation of Nogo receptor expression induces apoptosis of retinal ganglion cells in diabetic rats. Neural Regen Res 9:815–820
Ghosh AK, Osswald HL (2014) BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer’s disease. Chem Soc Rev 43:6765–6813
Mecocci P, Polidori MC (2012) Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta 1822:631–638
Acknowledgments
We acknowledge research funding from the NHMRC, ORIA, MQRDG and Hillcrest foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gupta, V., Gupta, V.B., Chitranshi, N. et al. One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina. Cell. Mol. Life Sci. 73, 4279–4297 (2016). https://doi.org/10.1007/s00018-016-2295-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-016-2295-x